NEW YORK (GenomeWeb) – Australian molecular diagnostics maker SpeeDx has inked distribution deals with AB Analitica in Italy and Immuno Diagnostic Oy in Finland to expand the firm's European distribution network.
The deals cover distribution of the SpeeDx ResistancePlus and PlexPCR tests.
The new distribution partners have "strong sales presence in their regions and close working relationships with the key customers" interested in the SpeeDx solutions, said Colin Denver, SpeeDx CEO, in a statement. The firm recently announced it had partnered with four other distributors in Europe, which combined cover Germany, Belgium, the Netherlands, Luxembourg, Switzerland, Spain, Estonia, Latvia, Lithuania, and Central Eastern Europe.
The firm's assays use multiplex qPCR to detect infectious disease pathogens and genetic markers of antibacterial resistance. Its ResistancePlus portfolio includes a CE-marked assay that can detect gonorrhea and determine genetic susceptibility to a common first-line drug, as well as a CE-marked assay for Mycoplasma genitalium and markers of resistance to a common treatment.
"Antibiotic resistance in sexually transmitted diseases is a top concern for authorities and testing bodies across Europe, and now more laboratories can access our ResistancePlus tests for Mycoplasma genitalium and gonorrhea to help address the real need for resistance-guided therapy," Denver said.
The SpeeDx PlexPCR portfolio, meanwhile, includes a multiplex test for herpes simplex viruses 1 and 2, varicella zoster virus, and Treponema pallidum, the spirochete bacteria that causes syphilis.
SpeeDx said it is currently developing a Mycoplasma genitalium assay that will detect resistance to second-line treatments and comprehensive multiplex panels for respiratory virus testing and respiratory bacterial infection testing in the PlexPCR portfolio.